Forte Biosciences, Inc. (FBRX) Stock
Healthcare · Biotechnology · US
$35.00
+33.23%
Last updated Jun 19, 2026 00:03 UTC
FBRX Key Statistics
Market Cap$486.00M
P/E (TTM)-7.43
P/S (TTM)—
P/B (TTM)84.46
Revenue (TTM)$0.00
EPS (TTM)$-4.71
Dividend Yield—
ROE (TTM)-98.36%
Net Margin0.00%
Gross Margin0.00%
52W High$35.79
52W Low$22.01
Analyst ViewBuy
Price Target$65.00
Employees14
Volume1,414,346
About Forte Biosciences, Inc.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
CEO: Paul A. Wagner. Company website
See FBRX live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open FBRX in Terminal See plans